Correlation between PD-L1 expression level and clinical benefit in 204 patients across malignancies at a single institution
| العنوان: | Correlation between PD-L1 expression level and clinical benefit in 204 patients across malignancies at a single institution |
|---|---|
| المؤلفون: | Kenneth P Byrd, Kruti Patel, Matthew K Stein, Panduka Nagahawatte, Ari M. Vanderwalde, Lee S. Schwartzberg, Michael Gary Martin |
| المصدر: | Journal of Clinical Oncology. 35:e14573-e14573 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Oncology, Correlation, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, medicine, Pd l1 expression, Single institution, business |
| الوصف: | e14573 Background: The utility of PD-L1 expression levels in predicting response to anti-PD-1 agents in many malignancies is uncertain. In this study, we describe outcomes of patients treated with anti-PD-1 agents by PD-L1 expression level. Methods: Molecular profiling of tumors in patients with newly diagnosed metastatic cancer was performed at West Cancer Center starting late 2014. Most profiling was performed by Caris, which in addition to NGS also reports PD-L1 expression (IHC, reported as percent expressed). Patients were included in this retrospective analysis if they were treated with an anti-PD-1 antibody and had available results from PD-L1 testing between 11/2014 and 11/2016. Time to treatment failure (TTF) was defined as time from first dose to documented progression, intolerance or death. Those without treatment failure were censored at the date of last contact. Pending formal retrospective RECIST review, clinical benefit rate (CBR) is reported. Results: 204 patients with reported PD-L1 expression started treatment with anti-PD-1 agents. Of these, 125 had non-small cell lung cancer, 31 had melanoma, 12 had renal cell carcinoma, and the remainder had other malignancies. 110 patients (54%) had PD-L1 expression level of 0%, 22 patients (11%) between 1-4%, 37 patients (18%) between 5-49%, and 35 patients (17%) >50%. Median TTF and CBR by PD-L1 overall and by malignancy are shown in the table below. Conclusions: Higher PD-L1 expression does appear to be associated with increased clinical benefit rate and time to treatment failure, though the highest levels of PD-L1 did not follow this pattern. Based on these surrogate endpoints, there appears to be substantial benefit with PD-1 inhibitor treatment even with 0% PD-L1 expression. Objective response rate will be presented. [Table: see text] |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::de81aff35c6991ebf2bb9c5b0f5330f4 https://doi.org/10.1200/jco.2017.35.15_suppl.e14573 |
| رقم الأكسشن: | edsair.doi...........de81aff35c6991ebf2bb9c5b0f5330f4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|